HeartBeam Reports 2025 Financial Results, Advances Toward Commercialization After FDA Clearance of 12-Lead ECG Software

HeartBeam (NASDAQ: BEAT) announced Q4 and full-year 2025 results, highlighting FDA clearance of its 12-lead ECG synthesis software, a limited market launch, and early enrollment in its ALIGN-ACS pilot study for heart attack detection.

Chicago Metrowire Staff
••Healthcare
HeartBeam Reports 2025 Financial Results, Advances Toward Commercialization After FDA Clearance of 12-Lead ECG Software

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, reported financial and operational results for the fourth quarter and full year ended Dec. 31, 2025. The company highlighted significant progress toward commercialization following U.S. Food and Drug Administration (FDA) 510(k) clearance of its 12-lead electrocardiogram (ECG) synthesis software in December 2025.

HeartBeam has initiated a limited market launch targeting concierge and preventive cardiology groups, securing its first commercial partnership with ClearCardio. The company also enrolled initial patients in its ALIGN-ACS pilot study, which evaluates the HeartBeam System for detecting heart attacks. Additional developments include the completion of a prototype extended-wear 12-lead ECG patch, a strategic collaboration with the Icahn School of Medicine at Mount Sinai to advance AI-enabled ECG algorithms, and the appointment of a new chief commercial officer to support growth initiatives.

The company's platform technology aims to create the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis in December 2025, is designed for portable use outside medical facilities, enabling physicians to identify cardiac health trends and acute conditions.

For the full year 2025, HeartBeam reported a net loss of $20.5 million compared to $17.8 million in 2024, reflecting increased investment in clinical development and commercialization. Research and development expenses rose to $10.2 million from $7.5 million in the prior year, driven by costs associated with the ALIGN-ACS study and product development. Selling, general, and administrative expenses increased to $11.5 million from $10.3 million, primarily due to higher personnel costs and commercialization activities. The company ended the year with $8.2 million in cash and cash equivalents.

HeartBeam holds over 20 issued patents related to its 3D ECG technology. The company's newsroom and full press release are available at https://ibn.fm/BEAT and https://ibn.fm/3KQqG, respectively. Forward-looking statements in this article involve risks and uncertainties as detailed in the company's SEC filings.

Blockchain Registration

QR Code for Blockchain Registration